Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec
March
NIH names Dr. Jon Lorsch director of the National Institute of General Medical Sciences
Press Release
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced today the selection of Jon R. Lorsch, Ph.D., as Director of the National Institute of General Medical Sciences. Dr. Lorsch is expected to join the NIH this summer. Read More...
BioHealth Innovation aims to help Maryland biotechs land government deals
Baltimore Business Journal
BioHealth Innovation Inc. in Rockville is launching a program to help small life sciences companies in Central Maryland land more government grants.
Read More...
New Spray Product Takes Aim at Salmonella on Poultry
Food Safety News
“A sneaky germ.” That’s how the U.S. Centers for Disease Control and Prevention describes Salmonella. The agency follows that uncomplimentary description with a warning that Salmonella can contaminate more than just poultry and eggs. “It sneaks its way into many foods — ground beef, pork, tomatoes, sprouts — even peanut butter,” says the CDC site.
Read More...
With Nacy’s guidance, Sequella taking on life-threatening diseases
Gazette.net
For 17 years, Carol A. Nacy was a career scientist and science manager for the Walter Reed Army Institute of Research, studying tropical, infectious diseases and publishing more than 100 papers. Read More...
Johns Hopkins researchers use a type of stem cells from human adipose tissue to chase migrating cancer cells
Press Release
In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient’s own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor.
Read More...
Neuralstem CEO, Richard Garr, Named To "Top 50 Global Stem Cell Influencers"
Press Release
Neuralstem, Inc. announced that CEO and President, Richard Garr, was listed as the 15th most influential person in the stem field in the "Top 50 Global Stem Cell Influencers," published by Total BioPharma, a division of Terrapinn, in advance of the World Stem Cells & Regenerative Medicine Congress 2013, in May.
Read More...
Noxilizer CEO: SAIAN aquisition a 'natural complement' for company
Baltimore Business Journal
Noxilizer Inc., a Baltimore sterilization company led by CEO Lawrence Bruder, has come a long way in a short time. Just this past November the company was celebrating its first U.S. customer for its signature nitrogen dioxide sterilization system, RTS 360 Industrial NO2 Sterilizer. Read More...
Noxilizer Acquires Japanese-Based SAIAN Corporation Assets And Expands Nitrogen Dioxide Sterilization Product Line For Global Life Science Marketplace
Press Release
Noxilizer, Inc. and SAIAN Corporation announced today Noxilizer’s asset acquisition of SAIAN Corporation. Both companies have been involved in developing nitrogen dioxide as a sterilization solution for pharmaceutical, biotech and medical device companies, as well as hospitals. Read More...
Intralytix Wins Regulatory Approval For Phage-Based Food Safety Product Effective Against Salmonella
Press Release
Intralytix, Inc. announced that its latest food safety product, SalmoFresh™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA). Read More...
Sequestration a blow to life sciences
Fierce Pharma
A total of $85 billion in across-the-board U.S. government spending cuts will be triggered in the absence of a last-minute Congressional deal to delay or end the threat of sequestration. Read More...
Sequestration puts speed bumps in drug review fast lane
Fierce Pharma
Drugmakers paid a toll to build the FDA fast lane for drug approval, only to find it full of speed bumps created by the sequestration law that went into effect. Read More...
February
New Bioterrorism Vaccine Gets First Test In Humans
PR Newswire
Integrated BioTherapeutics (IBT) announces the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine "STEBVAX" in healthy adults. Read More...
Stem cell biotech Osiris Therapeutics wins overseas
Gazette.net
Osiris Therapeutics announced a couple of legal and regulatory victories this week. Read More...
Hopkins researcher receives new award to spotlight scientists
Baltimore Sun
A Johns Hopkins doctor known for his work using genetics to test for and treat colon and other cancers is one of the inaugural winners of a new $3 million award meant to spotlight scientists not known to the average person.
Read More...
Cytomedix To Raise Up To $27.5 Million As Part Of A Comprehensive 2013 Financing Plan
Press Release
Cytomedix, Inc., a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today the execution of a comprehensive financing plan for 2013. Included in these executed transactions is a tranched $7.5 million senior secured term loan facility, a $5 million equity raise, and a $15 million committed equity facility. Read More...
United Therapeutics heads back to the FDA
Gazette.net
Four months after the Food and Drug Administration shot down United Therapeutics’ application to market a tablet version of its drug for pulmonary arterial hypertension, the Silver Spring company has reapplied to the regulatory agency. Read More...
NW BIO Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe
Press Release
Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, building upon nearly three years of manufacturing development, regulatory processes and clinical preparations in Europe, the Company has named a leading international contract research organization (CRO) to manage the Company’s 312-patient Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer in Europe. Read More...
Life Technologies Receives FDA 510(k) Clearance For Diagnostic Use Of Sanger Sequencing Platform And HLA Typing Kits
TheStreet.com
Life Technologies, a global co w/ R&D facilities in Frederick, receives FDA 510(k) clearance for Dx use of CE Sequencing Systems & HLA Assay.
Read More...
Actavis Details Strategy for Continued Long-Term Growth
Press Release
Actavis, Inc. (NYSE: ACT), formerly Watson Pharmaceuticals, Inc., today provides an in-depth look into the newly combined company’s global commercial operations, diversified business structure and outlook for continued longterm growth during its fourth annual Investor Meeting in New York. Read More....
January
Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThrax
Press Release
Emergent BioSolutions Inc. today announced the initiation of a Phase 2 study designed to evaluate non-interference of BioThrax® (Anthrax Vaccine Adsorbed) when administered in conjunction with antibiotics.
Read More...
MaxCyte® VLX and STX Transient Transfection Systems Are Acquired by Paragon Bioservices for Use in Vaccine and Protein Manufacturing
Press Release
MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is pleased to announce that Paragon Bioservices has acquired both the MaxCyte VLX® Large Scale Transfection System and the MaxCyte STX® Scalable Transfection System for use in contract manufacturing of recombinant proteins, antibodies, viral vectors, vaccines, and VLPs.
Read More...
Scientists Seek Stem Cell Cure For Spinal Cord Injuries
WAMU.org
Neuralstem, a Rockville-based biotech company, has just been approved by the FDA to begin implanting stem cells into people with spinal cord injuries. While there's a long scientific journey ahead, this trial could mean hope for paraplegic and quadriplegic patients all over the world.
Read More...
BARDA Continues Novavax' Influenza Vaccine Programs Following In-Process Review
GlobeNewsWire.com
Novavax, Inc. today announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review (IPR) of Novavax' contract covering the company's recombinant virus-like particle (VLP) vaccine candidates for pandemic and seasonal influenza. Read More...
At CytImmune, Lawrence Tamarkin is on a gold rush
Gazette.net
Lawrence Tamarkin was on the brink of a discovery that could change the paradigm of cancer treatment delivery when the Great Recession forced his company to slow down. But with some key contacts and flexibility, Tamarkin says he is now ready to show the world what his technology can do.
Read More...
Despite growing demand, MedImmune still has flu vaccines on hand
Gazette.net
With a more virulent-than-usual influenza season well under way, MedImmune says it’s ready to meet vaccine demands, even as it prepares to release a more protective, four-strain vaccine next season.
Read More...
Rexahn Pharmaceuticals names new CEO
Washington Business Journal
Rockville-based Rexahn Pharmaceuticals has named Dr. Peter Suzdak as chief executive officer. Read More...
Bahija Jallal to replace Peter Greenleaf as head of MedImmune
Washington Business Journal
MedImmune executive Bahija Jallal will be the new chief of the Gaithersburg biotech under a leadership shuffle by parent company AstraZeneca.
Read More...
Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
Press Release
Neuralstem, Inc. announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. This open-label, multi-site study, will enroll up to eight patients with thoracic spinal cord injuries (T2-T12), who have an American Spinal Injury Association (AIS) A level of impairment, between one and two years after injury. Read More...
CytImmune and AstraZeneca to Research Potential New Nanomedicine for Cancer
Press Release
CytImmune and AstraZeneca have entered into an agreement to study the feasibility of a new cancer nanomedicine that will bind an oncology compound from AstraZeneca to CytImmune’s CYT--‐6091 nanomedicine platform.
Read More...
Daiichi Sankyo and Amplimmune Announce Strategic Alliance to Develop AMP-110 Therapy for Autoimmune Disease
Press Release
Daiichi Sankyo, Co., Ltd. and Amplimmune, Inc. announced today that they have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). The collaboration will focus on development of AMP-110, a potential immune modulation therapy for autoimmune diseases. Read More...
Maryland Innovation Initiative Awards Funding to First Three Research Projects
Press Release
The Maryland Innovation Initiative (MII), which accelerates commercialization and technology transfer from university labs to start-up companies, announced its first three awards today, totaling $299,678. These three awards were given to BOSS Medical LLC, a university start-up company, and two Johns Hopkins University faculty members. The three awards were given through the Innovation Commercialization Program, which provides funding to support the commercialization of qualified university technologies at three distinct stages: pre-commercial translational research (Phase I), commercialization planning (Phase II) and early-stage product development (Phase III). Read More...
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products
Press Release
MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced it has entered into a license agreement with Gilead Sciences, Inc. for the development and commercialization of Dual-Affinity Re-Targeting (DART™) products directed at up to four undisclosed targets. MacroGenics’ DART technology is a proprietary, bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens.
Read More...
Telcare is tied for 3rd place at CES
Telcare
Telcare is tied for 3rd place in the Last Gadget Standing competition at the 2013 Consumer Electronics Show. Telcare is being recognized for their wireless glucose blood meter. To cast your vote, click here.
Immunovaccine Reports Positive Results from Ongoing Study of DepoVax™-Based Anthrax Vaccines
Press Release
Immunovaccine Inc., a clinical stage vaccine company, today announced positive results from an immunogenicity study that evaluated anthrax vaccines formulated in the Company’s DepoVax™ platform. Read More...
December
Plant Sensory Systems Awarded $1.8M from ARPA-E to Engineer Beets for Biofuel
BioSpace.com
The award will support a three-year program to develop an enhanced energy (sugar) beet, optimized for biofuel productions. Read More
Controversial FDA Official Tom Laughren Retires
BioSpace.com
One of the more controversial figures at the FDA over the past decade quietly retired late last month. Tom Laughren, who was the director of the Division of Psychiatry Products in the Office of New Drugs in the Center for Drug Evaluation and Research, departed the FDA after spending nearly 20 years at the agency, an FDA spokeswoman confirms. Read More...
Cytomedix Inc. Announces Positive Results With Angel® cPRP in Veterinary Application
BioSpace.com
Cytomedix, Inc., a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that positive data on the Angel® cPRP system in a veterinary application -- treatment of persistent mating induced endometritis (PMIE) in mares -- were recently presented at the 3rd annual conference of the North American Veterinary Regenerative Medicine Association (NAVRMA) in Savannah, GA.
Read More...
Profectus HIV vaccine advances in trial
Gazette.net
A Baltimore biotech reported that its experimental HIV vaccine showed promising results in a phase 1 clinical study. Read More...
Medical device makers to be hit with tax in 2013
Washington Business Journal
Starting Jan. 1, medical device manufacturers must pay a new 2.3 percent excise tax on their gross revenues, regardless of profits, to raise $1.8 billion in federal revenue in 2013 and $20 billion through 2019, as part of the health care reform legislation. Read More...
November
Teva Pharmaceuticals Industries boosts stake in Rexahn Pharmaceuticals
Washington Business Journal
Teva Pharmaceuticals Industries Ltd. has boosted its stake in Rockville-based Rexahn Pharmaceuticals Inc. and will increase its involvement in developing Rexahn's lead anti-cancer drug. Read More...
MdBio Foundation names former Washington Redskins exec new CEO
Washington Business Journal
A former Washington Redskins charity director has joined MdBio Foundation as its new CEO. Brian Gaines, former executive director of the Washington Redskins Charitable Foundation will oversee MdBio Foundation’s daily operations, fundraising and development, the Baltimore Business Journal reported.
Read More...
Noxilizer hits milestone with first sale of sterilization system
Baltimore Business Journal
Baltimore biotech firm Noxilizer sold its first sterilization system to an Indianapolis company, a deal that could be worth up to $340,000 over the next three years and sets the stage for expanding the company’s operations from services to products. Read More...
Tech Council of Maryland chief Art Jacoby to depart in February
Washington Business Journal
Art Jacoby, who set an ambitious agenda for the Tech Council of Maryland following his quiet promotion to CEO this summer, will leave the trade group early next year. Read More...
Biotech veterans take reins at Biota — the new Nabi
Gazette.net
Biota Pharmaceuticals — formerly Nabi Biopharmaceuticals — has a new team at the top. Read More...
R. Don Elsey out as Emergent BioSolutions CFO
Washington Business Journal
R. Don Elsey has resigned as chief financial officer of Emergent BioSolutions Inc., a role he’s held since 2006, the Rockville biotech announced Monday. Read More...
MedImmune creating drug pipeline for AstraZeneca
The Baltimore Sun
MedImmune leaders say they are entering a prime phase in drug development, with several projects moving into final patient trials and a growing share of AstraZeneca's overall drug pipeline. Given intense competition in the industry, success will depend on how each gamble pays off in the laboratory. Read More...
Synthetic Biologics, Inc. (AEN) Announces $10.8 Million Financing
Biospace
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced that it has entered into definitive stock purchase agreements with accredited investors to raise approximately $10.8 million in a private placement financing. Read More...
Another Supernus Pharmaceuticals (SUPN) Epilepsy Drug Gets FDA Nod
Biospace
Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company, received approval from the Food & Drug Administration (the "FDA") for Oxtellar XR , a novel once-daily extended release formulation of oxcarbazepine (formerly known as SPN-804). Read More...
October
United Therapeutics drug rejected by FDA
Baltimore Business Journal
United Therapeutics Corp.'s new drug application for a tablet version of its treatment for pulmonary arterial hypertension has been rejected by the Food and Drug Administration, more than a year after disappointing results in late-stage clinical trials. Read More...
Another Supernus Pharmamaceuticals (SUPN) Epilepsy Drug gets FDA Nod
BioSpace
Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company, received approval from the Food & Drug Administration (the "FDA") for Oxtellar XR , a novel once-daily extended release formulation of oxcarbazepine (formerly known as SPN-804). Read More...
GlycoMimetics announces the publication of a scientific paper in Nature Medicine
Press Release
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that preclinical data related to its lead drug candidate, GMI-1070, has been published in the current issue of Nature Medicine. Read More...
Aeras Global TB Vaccine Foundation, GlaxoSmithKline (GSK) Collaborate onTB Vaccine
BioSpace
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E* adjuvant. Read More...
MedImmune (AZN) Inks Pact With Two Leading Cancer Institutes to Advance R&D
BioSpace
The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer. Read More...
UMBC researchers win $1.4M grant for diabetes study
Baltimore Business Journal
Two researchers at the University of Maryland, Baltimore County received a nearly $1.4 million grant from the National Institutes of Health to study how people with diabetes manage the condition. Read More...
Baxter leads Gliknik Series B Investment
Press Release
Gliknik Inc., a privately held biopharmaceuticals company creating new therapies for cancer and immune / inflammatory disorders, today announced that it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. Read More...
September
William E. Proudford Sickle Cell Fund Honors Glycomimetics, Inc. with "Unsung Hero" Award
Press Release
GlycoMimetics, Inc. a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced today that the William E. Proudford Sickle Cell Fund presented the company with its 2012 Unsung Hero Award. Read More...
MedImmune may expand Gaithersburg Campus
Baltimore Business Journal
MedImmune executives hinted this week that an expansion of the Gaithersburg-based biotech's campus may be coming soon. Read More...
MacroGenics and Serview Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DARTTM products
FierceBioTech
MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately‐held pharmaceutical company, announced today that they have entered into an option agreement for the development and commercialization of Dual‐Affinity Re‐Targeting (DARTTM) products directed at three undisclosed tumor targets. Read More...
MacroGenics, Inc. Could Earn More Than $1 Billion Through New Servier Alliance
BioSpace
MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets. Read More...
Army awards $2.67M to startup to develop miniature device to assess TBI
MedCity News
A Bethesda, Maryland startup BrainScope has been awarded a $2.67 million contract over two years to develop a miniature, hand-held, non-invasive medical devices that can rapidly evaluate traumatic brain injury in the field. Read More...
NeuralStem Inc. Gains on Stem Cell Therapy for Paralyzed Rats
BioSpace
Neuralstem, Inc. announced that its neural stem cells were part of a study, "Long-Distance Growth and Connectivity of Neural Stem Cells After Severe Spinal Cord Injury: Cell-Intrinsic Mechanisms Overcome Spinal Inhibition," published online today in a leading scientific journal CELL (http://www.cell.com/current). Read More...
NeuralStem Inc. to Raise $7.0 Million in Registered Direct Offering
BioSpace
Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share. The gross proceeds to Neuralstem from this offering are expected to be $7.0 million, before deducting placement agent fees and other estimated offering expenses payable by Neuralstem. The offering is expected to close on or about September 19, 2012, subject to customary closing conditions. Read More...
Intralytix Awarded Phase II Grant for Managing Salmonella in Food
Press Release
Intralytix, Inc. announced today that it has been awarded a grant under a National Institute of Food And Agriculture (NIFA) / United States Department of Agriculture (USDA) Small Business Innovative Research (SBIR) Grants Program for the development of a phage preparation for reducing or eliminating Salmonella contamination in foods. Read More....
The Symposium on Advanced Wound Care (SWAC Fall)
Poster presenters will be available September 13 from 5:30 p.m. to 6:15 p.m. local time, and posters will be available for viewing September 12 and September 13 from 8:00 a.m. to 4:00 p.m. local time. The following posters highlighting Cytomedix’s PRP technology will be presented at SAWC Fall 2012.
· Aged Spinal Cord Injury Veterans with Recalcitrant Pressure Ulcers Treated with Platelet-Rich Plasma Gel by Natalie Tukpah, RN, CWOCN and Karen Evans, M.D., Veterans Affairs Medical Center, Washington D.C. Poster Number CS-042.
Healing Complex, Severe Diabetic and Ischemic Wounds in Japan Using Platelet-Rich Plasma Gel by Chugo Rinoie, DPM, ABPO, CWS, Chief of Podiatric Surgery, Wound Healing Center, Methodist Hospital of Southern California, Arcadia, Calif., and Medical Director, Millennia Wound Management, Inc., Los Angeles. Poster Number CR-021.
Advancing Wound Healing Trajectory with Platelet Rich Plasma Gel in Stalled NPWT Wounds by Janice Wilson, RN, CWOCN and Karl Branch, RN, Asheville Specialty Hospital, Asheville, N.C. Poster Number CR-029. More Info
Foodem gets $75,000 investment from TEDCO to build online wholesale food portal
Baltimore Sun
One of the latest tech startups to get a footing in Baltimore is Foodem, a website started by a University of Maryland College Park grad a few years ago that aims to build a transparent marketplace for commercial food buyers and distributors. Read More...
Akonni Gets $500K SBIR Grant for Array Consumables
GenomeWeb Daily News
Akonni Biosystems today said that it has received a $498,780 Phase 2 SBIR award from the National Science Foundation to further develop its Lab-on-a-Film microarray consumable technology. Read More...
August
KeyGene, AGI Ink Deal Covering Whole Genome Profiling Technology
GenomeWeb
Agricultural genomics firm KeyGene and the Arizona Genome Institute today announced an agreement for the use of the Wageningen, Netherlands-based firm's Whole Genome Profiling method in sequencing-based physical mapping projects. Read More...
Telcare Raises $25.5 Million in Financing, Led by Sequoia Capital
Press Release
Telcare, Inc., developer of the first FDA-cleared wireless glucose monitoring system for people with diabetes, announced today that it has secured $25.5 million in equity funding as the first close of a Series B financing led by Sequoia Capital, Menlo Park, CA. Read More...
Fyodor Biotechnologies awarded a National Science Foundation SBIR Grant
Press Release
Fyodor Biotechnologies, a Baltimore-based diagnostic and biopharmaceutical company, announced today that the National Science Foundation has awarded the company a Small Business Innovation Research (SBIR) Phase I grant. With the $150,000 funding, Fyodor plans to develop a novel recombinant antibody to be used in a urine-based test for the point-of-need detection of Leptospirosis. Read More...
Fyodor Biotechnologies expands within University of Maryland BioPark
Press Release
Fyodor Biotechnologies Inc. announced today that it has expanded its office and laboratory space at the University of Maryland BioPark in Baltimore, moving from the BioPark’s BioInnovation Center (BIC) at 801 West Baltimore Street to the expanded BioInnovation Center across the street at 800 West Baltimore Street. The move is prompted by Fyodor’s advancing research and development activities, including those related to its urine-based malaria diagnostic assay. Read More...